Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.

Al-Khanaty A, Chen D, Walbaum J, Hennes D, Delgado C, Dinneen E, Eapen R, Hofman MS, Azad AA, Murphy DG, Lawrentschuk N, Perera M

Open source

DOI: 10.1111/bju.70283
Published: 2026 Sep
Container: BJU international
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/bju.70283,
  title = {Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.},
  author = {Al-Khanaty A and Chen D and Walbaum J and Hennes D and Delgado C and Dinneen E and Eapen R and Hofman MS and Azad AA and Murphy DG and Lawrentschuk N and Perera M},
  year = {2026},
  journal = {BJU international},
  doi = {10.1111/bju.70283},
  url = {https://doi.org/10.1111/bju.70283}
}

RIS

TY  - JOUR
TI  - Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.
AU  - Al-Khanaty A
AU  - Chen D
AU  - Walbaum J
AU  - Hennes D
AU  - Delgado C
AU  - Dinneen E
AU  - Eapen R
AU  - Hofman MS
AU  - Azad AA
AU  - Murphy DG
AU  - Lawrentschuk N
AU  - Perera M
PY  - 2026
JO  - BJU international
DO  - 10.1111/bju.70283
UR  - https://doi.org/10.1111/bju.70283
ER  -

APA

A, A., D, C., J, W., D, H., C, D., E, D., R, E., MS, H., AA, A., DG, M., N, L., & M, P. (2026). Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.. BJU international. https://doi.org/10.1111/bju.70283

Source records

pubmed · retrieved 2026-09-26T00:25:01.012Z